Alane B O'Connor1, Brett Uhler2, Liam M O'Brien3, Kyle Knuppel2. 1. Dartmouth Medical School, Maine Dartmouth Family Medicine Residency, 149 North Street, Waterville, ME 04901, United States. Electronic address: aoconnor@mainegeneral.org. 2. Maine Dartmouth Family Medicine Residency, 149 North Street, Waterville, ME 04901, United States. 3. Department of Mathematics and Statistics, Colby College, School of Community and Population Health, University of New England, 5838 Mayflower Hill, Waterville, ME 04901, United States.
Abstract
AIM: To determine variables related to treatment retention in women six and twelve months postpartum that were in medication treatment using buprenorphine during pregnancy. METHODS: This retrospective cohort study of 190 maternal-infant dyads exposed to buprenorphine during pregnancy examines rates of treatment retention at six and twelve months postpartum and also analyzes a variety of potential predictors of treatment retention including illicit drug use in the third trimester, delayed entry into medication treatment and co-occurring mental health diagnoses requiring prescription medication. RESULTS: At 12months postpartum, women appeared more likely to remain in medication treatment if they entered treatment early in pregnancy (defined as either being in treatment at the time of conception, p=0.001, or entering medication treatment prior to 13weeks gestation, p=0.037). Being prescribed an antidepressant medication during the third trimester was also associated with enhanced treatment retention at six months postpartum (p=0.005). At both six and twelve months postpartum, the use of illicit drugs (including opioids, cocaine and benzodiazepines) during the third trimester was negatively correlated with treatment retention (p=0.012 and p<0.001, respectively). CONCLUSIONS: Early access to medication treatment is associated with treatment retention in women prescribed buprenorphine during pregnancy. This has important public health implications as access to treatment is limited in many parts of the country and many women are only able to obtain treatment after becoming pregnant. Being prescribed an antidepressant medication during pregnancy may enhance treatment retention, supporting the work of previous authors.
AIM: To determine variables related to treatment retention in women six and twelve months postpartum that were in medication treatment using buprenorphine during pregnancy. METHODS: This retrospective cohort study of 190 maternal-infant dyads exposed to buprenorphine during pregnancy examines rates of treatment retention at six and twelve months postpartum and also analyzes a variety of potential predictors of treatment retention including illicit drug use in the third trimester, delayed entry into medication treatment and co-occurring mental health diagnoses requiring prescription medication. RESULTS: At 12months postpartum, women appeared more likely to remain in medication treatment if they entered treatment early in pregnancy (defined as either being in treatment at the time of conception, p=0.001, or entering medication treatment prior to 13weeks gestation, p=0.037). Being prescribed an antidepressant medication during the third trimester was also associated with enhanced treatment retention at six months postpartum (p=0.005). At both six and twelve months postpartum, the use of illicit drugs (including opioids, cocaine and benzodiazepines) during the third trimester was negatively correlated with treatment retention (p=0.012 and p<0.001, respectively). CONCLUSIONS: Early access to medication treatment is associated with treatment retention in women prescribed buprenorphine during pregnancy. This has important public health implications as access to treatment is limited in many parts of the country and many women are only able to obtain treatment after becoming pregnant. Being prescribed an antidepressant medication during pregnancy may enhance treatment retention, supporting the work of previous authors.
Authors: Michael R Richards; Ashley A Leech; Bradley D Stein; Melinda B Buntin; Stephen W Patrick Journal: Health Serv Res Date: 2021-12-18 Impact factor: 3.402
Authors: Davida M Schiff; Erin C Work; Serra Muftu; Shayla Partridge; Kathryn Dee L MacMillan; Jessica R Gray; Bettina B Hoeppner; John F Kelly; Shelly F Greenfield; Hendrée E Jones; Timothy E Wilens; Mishka Terplan; Judith Bernstein Journal: J Subst Abuse Treat Date: 2022-03-18
Authors: Davida M Schiff; Timothy C Nielsen; Bettina B Hoeppner; Mishka Terplan; Scott E Hadland; Dana Bernson; Shelly F Greenfield; Judith Bernstein; Monica Bharel; Julia Reddy; Elsie M Taveras; John F Kelly; Timothy E Wilens Journal: Am J Obstet Gynecol Date: 2021-04-15 Impact factor: 10.693